Viagra Shows Promise as Potential Treatment for Rare, Deadly Childhood Disease
March 24, 2026 – In a surprising development, sildenafil – the active ingredient in Viagra – is showing potential as a treatment for Leigh syndrome, a rare and often fatal genetic disorder that primarily affects children. The findings offer a glimmer of hope for families facing this devastating diagnosis, as currently You’ll see no approved therapies to slow or prevent the disease’s progression.
Leigh syndrome impacts roughly one in 40,000 births and disrupts the function of mitochondria, the energy-producing structures within cells. This disruption leads to a cascade of debilitating effects, including seizures, muscle weakness, paralysis, and developmental delays. Most children with Leigh syndrome do not survive past the age of three.
Initial research, published in the journal Cell by researchers at Charité – Universitätsmedizin Berlin, indicated improvements in muscle strength and metabolism in patients with the condition. A small pilot study involving six patients, ranging in age from 9 months to 38 years, demonstrated positive effects on disease progression. According to reports from Nationale Zorggids, some patients experienced a tenfold increase in walking distance during treatment.
Researchers discovered that sildenafil appeared to remedy undesirable molecular alterations observed in patients with Leigh syndrome and activated genes that are typically expressed during brain formation. The unexpected benefit of sildenafil was initially explored due to its known function as a treatment for erectile dysfunction in adults, but It’s also used for certain cases of pulmonary hypertension in children because of its ability to dilate blood vessels.
The study also found that patients treated with sildenafil recovered more quickly from metabolic crises, periods where the body’s energy regulation is severely disrupted. De Gelderlander reported that the syndrome particularly affects children, and those diagnosed face a challenging prognosis due to its rarity.
A larger European clinical trial, planned for 2026, will involve 60 to 70 patients. IBTimes notes that this trial represents “the first chance of a cure, perhaps the exceptionally first chance of a cure” for Leigh syndrome. The findings could potentially reshape treatment approaches for this devastating condition and offer renewed hope to affected families.
